Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 224
Group description: Includes all subjects who were randomized to and treated with investigational product
Eligibility criteria:
Inclusion Criteria:

Sign Informed Consent
Use of condom by sexually active males for the entire duration of the study.
Best corrected visual acuity of 55 or greater in each eye as measured by ETDRS (letters read method).
Able and willing to comply with study protocol and follow protocol instructions.
Able to avoid any of the topical ocular or systemic excluded medications during the entire study period.
At least 1 year subject-reported or physician-diagnosed history (prior to Screen Visit) of allergic conjunctivitis during the ragweed season.
Positive skin prick test for short ragweed allergen within 12 months prior to Screen Visit.
Significant staff-assessed ocular redness in at least one region in each eye within the 3 hour period of allergen exposure in the EEC (Screen Visits).
Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 1 week following the last dose of investigational product.
Presence of any ocular infection, history of ocular Herpes (simplex or zoster) or adenoviral infection in either eye.
History of any ocular infection, physician or subject diagnosed, within 30 days prior to Screen Visit.
Presence of glaucoma, past history of, or diagnosis of glaucoma or ocular hypertension.
Presence of blepharitis, active rosacea affecting the ocular adnexa, meibomian gland dysfunction, follicular conjunctivitis, intraocular inflammation, or preauricular lymphadenopathy or any other ophthalmic abnormality that may affect the study outcomes.
Corneal conditions affecting the corneal structure.
Unwilling to discontinue contact lens wear during the study period.
Any ocular surgery including ocular laser procedures within 1 year prior to Screen Visit.
Current or recent (<6 months prior to Screen Visit) history of severe, unstable, or uncontrolled autoimmune, neurological, cardiovascular, hematological, hepatic, renal, psychological, respiratory, gastrointestinal and/or immunological disease or evidence of other diseases based upon a review of medical history and/or physical examination that, in the opinion of the Investigator, would preclude safe subject participation in the study.
Receiving treatment for anxiety and/or depression at the Screen Visit; any history of suicide attempt.
Participation in any investigational study within 30 days of Screen Visit or concomitantly with this study.
Known contraindications or hypersensitivities to any of the study medications or their components
Confirmed (by physician or optometrist) diagnosis of dry eye.
History of sensitivity or adverse reaction to steroids.
Known allergic reaction that is unresponsive to corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDS).
Physician diagnosed asthma (except inactive childhood asthma and exercise-induced asthma).
Evidence of active inflammation in the eye as determined by the dilated fundus examination conducted at Screen C Visit.
Any corneal swelling or haze as determined by the slitlamp examination conducted at Screen C Visit.
Other protocol-defined exclusion criteria may apply.